

Foamix Pharmaceuticals Ltd.  
Form 8-K  
October 01, 2018

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities and Exchange Act of 1934  
Date of Report (Date of earliest event reported): October 1, 2018

FOAMIX PHARMACEUTICALS LTD.  
(Translation of registrant's name into English)

Israel	001-36621	N/A
(State or		(IRS
other	(Commission	Employer
jurisdiction	File Number)	Identification
of		No.)
incorporation)		

2 Holzman Street,	
Weizmann	
Science Park	
Rehovot, Israel	7670402
(Address of	(Zip
principal	Code)
executive offices)	

+972-8-9316233  
(Registrant's telephone number, including  
area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

Item 7.01. Regulation FD Disclosure.

On October 1, 2018, Foamix Pharmaceuticals Ltd. (the "Company") issued a press release entitled, "Foamix Announces Additional Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne."

On October 2, 2018, the Company will present these additional topline results along with an overall corporate update at the Cantor Fitzgerald Global Healthcare Conference. Updated presentation materials are available on the Company's website under "Investors – Events and Presentations" at [www.foamix.com](http://www.foamix.com).

The press release is being furnished hereto as Exhibit 99.1.

The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as expressly set forth in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
--------------------	--------------------

<u>99.1</u>	<u>Press release dated October 1, 2018.</u>
-------------	---

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 1, 2018

FOAMIX PHARMACEUTICALS LTD.

By: /s/ Ilan Hadar  
Ilan Hadar  
Chief Financial Officer & Country Manager

---